Abstract

BackgroundChronic obstructive pulmonary disease (COPD) exacerbations are accompanied with increased systemic inflammation, which accelerate the pulmonary function injury and impair the quality of life. Prompt and effective treatments for COPD exacerbations slow down the disease progression, but an objective instrument to assess the efficacy of the treatments following COPD exacerbations is lacking nowadays. The COPD Assessment Test (CAT) is an 8-item questionnaire designed to assess and quantify health status and symptom burden in COPD patients. We hypothesize that the change in CAT score is related to the treatment response following COPD exacerbations.Methods78 inpatients with clinician-diagnosed acute exacerbation of COPD (AECOPD) completed the CAT, St George’s Respiratory Questionnaire (SGRQ) and modified Medical Research Council (mMRC) Dyspnea Scale both at exacerbation and the 7th day of therapy, and a subgroup of 39 patients performed the pulmonary function test. Concentrations of serum C-reactive protein (CRP) and plasma fibrinogen were assayed at the same time. Correlations between the CAT and other measurements were examined.ResultsAfter 7 days’ therapy, the CAT and SGRQ scores, mMRC grades, as well as the concentrations of CRP and fibrinogen all decreased significantly (P < 0.001). Meanwhile, the FEV1% predicted had a significant improvement (P < 0.001). The CAT scores were significantly correlated with concurrent concentrations of CRP and fibrinogen, SGRQ scores, FEV1% predicted and mMRC grades (P < 0.05). The change in CAT score was positively correlated with the change of CRP (r = 0.286, P < 0.05), SGRQ score (r = 0.725, P < 0.001) and mMRC grades (r = 0.593, P < 0.001), but not with fibrinogen (r = 0.137, P > 0.05) or FEV1% predicted (r = -0.101, P > 0.05). No relationship was found between the changes of SGRQ score and CRP and fibrinogen (P>0.05).ConclusionsThe CAT is associate with the changes of systemic inflammation following COPD exacerbations. Moreover, the CAT is responsive to the treatments, similar to other measures such as SGRQ, mMRC dyspnea scale and pulmonary function. Therefore, the CAT is a potentially useful instrument to assess the efficacy of treatments following COPD exacerbations.

Highlights

  • Chronic obstructive pulmonary disease (COPD) exacerbations are accompanied with increased systemic inflammation, which accelerate the pulmonary function injury and impair the quality of life

  • Subjects The study involved patients with clinician-diagnosed COPD exacerbation, which defined as an acute event characterized by a worsening of respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication [2,17]

  • The COPD Assessment Test (CAT) scores were significantly correlated with concurrent levels of C-reactive protein (CRP) and fibrinogen, modified Medical Research Council (mMRC) grades, St George’s Respiratory Questionnaire (SGRQ) scores and FEV1% predicted

Read more

Summary

Introduction

Chronic obstructive pulmonary disease (COPD) exacerbations are accompanied with increased systemic inflammation, which accelerate the pulmonary function injury and impair the quality of life. Clinicians routinely use various methods to assess the health status and response to treatments of COPD patients [5], but a simple and objective instrument to evaluate the treatments response following AECOPD is still lacking currently. The COPD Assessment Test (CAT) is a recently introduced, patient-completed instrument to assess and quantify health-related quality of life and symptom burden in patients of COPD [6,7]. It comprises 8 questions, each presented as a semantic 6-point (0–5) differential scale, providing a total score out of 40. The CAT has been translated into many languages and used worldwide, including China [14], but as yet no data is available on whether the CAT can be used to assess the response to treatments at exacerbations or therapeutic interventions in China

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call